REGENXBIO Inc.

REGENXBIO Inc. develops AAV‑gene therapies via its proprietary NAV platform, driving growth with a Phase‑III DMD candidate (RGX‑202) and multiple retinal, lysosomal, and lipid disorder programs, while licensing the platform to partners.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 353
HQ: Rockville

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
RGNX	REGENXBIO Inc. Cap: 0.7B	EQUITY	NMS	USD	US75901B1070	Active	📈